X0306 4 2021-03-01 0 0001714899 Denali Therapeutics Inc. DNLI 0001437435 Tessier-Lavigne Marc C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2021-03-01 4 S 0 18770 64.361 D 2723526 D Common Stock 2021-03-01 4 S 0 37445 65.634 D 2686081 D Common Stock 2021-03-01 4 S 0 18316 66.554 D 2667765 D Common Stock 2021-03-01 4 S 0 14945 67.57 D 2652820 D Common Stock 2021-03-01 4 S 0 6011 68.504 D 2646809 D Common Stock 2021-03-01 4 S 0 3482 69.589 D 2643327 D Common Stock 2021-03-01 4 S 0 1031 71.351 D 2642296 D The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.08 to $65.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The Reporting Person reported a prior award of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 3,253 previously reported restricted stock units. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.145 to $66.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.155 to $67.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.155 to $68.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.155 to $69.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.23 to $69.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.68 to $71.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Tyler Nielsen, by power of attorney 2021-03-03